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 2 
ABSTRACT 30 
Low muscle oxidative capacity contributes to exercise intolerance in chronic obstructive pulmonary 31 
disease (COPD). Near-infrared spectroscopy (NIRS) allows non-invasive determination of the 32 
muscle oxygen consumption (ǚ2) recovery rate constant (k), which is proportional to oxidative 33 
capacity assuming two conditions are met: 1) exercise intensity is sufficient to fully-activate 34 
mitochondrial oxidative enzymes; 2) sufficient O2 availability. We aimed to determine 35 
reproducibility (coefficient of variation, CV; intraclass correlation coefficient, ICC) of NIRS k 36 
assessment in the gastrocnemius of 64 participants with (FEV1 64±23%predicted) or without COPD 37 
(FEV1 98±14%predicted). 10-15s dynamic contractions preceded 6min of intermittent arterial 38 
occlusions (5-10s each, ~250mmHg) for k measurement. k was lower (P<0.05) in COPD 39 
(1.43±0.4min-1; CV=9.8±5.9%, ICC=0.88) than controls (1.74±0.69min-1; CV=9.9±8.4%; ICC=0.93). 40 
Poor k reproducibility was more common when post-contraction ǚ2 and deoxygenation were 41 
low, suggesting insufficient exercise intensity for mitochondrial activation and/or the NIRS signal 42 
contained little light reflected from active muscle. The NIRS assessment was well tolerated and 43 
reproducible for muscle dysfunction evaluation in COPD. 44 
 45 
 46 
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1. INTRODUCTION 51 
Chronic obstructive pulmonary disease (COPD) is characterized by dyspnea on exertion, with 52 
subsequent reduced exercise tolerance and quality of life. Skeletal muscle dysfunction is a systemic 53 
consequence of COPD that also contributes to increased morbidity and mortality in this population 54 
(Agustí et al., 2003; Casaburi et al., 2001; Decramer et al., 2008; Maltais et al., 2000, 2014; Nici, 55 
2000; Vogiatzis and Zakynthinos, 2012; Wounters et al., 2002). Morphological and structural 56 
skeletal muscle alterations in COPD are especially prevalent in the locomotor muscles, and include 57 
atrophy and weakness, loss of type I fibers, loss of muscle oxidative capacity and mitochondrial 58 
dysfunction, among others (Allaire et al., 2004; Coronell et al., 2004; Couillard and Prefaut, 2005; 59 
Engelen et al., 2000; Gosker et al., 2002, 2007; Maltais et al., 2014; Picard et al., 2008; Whittom et al., 60 
1998). Amelioration of these muscular alterations contributes to the substantial benefits of 61 
pulmonary rehabilitation in COPD patients (Maltais et al., 2014). 62 
 63 
The prevalence and progression of the loss of muscle oxidative phenotype in relation to disease 64 
severity is still unclear, and this is partly because measurement of muscle oxidative capacity 65 
requires an invasive biopsy or complex 31P magnetic resonance spectroscopy assessments. In 66 
review, Meyer et al. (2013) showed that low muscle oxidative capacity and increased reactive 67 
oxygen species production was evident in skeletal muscle across all spirometric stages of COPD 68 
disease severity. Furthermore, Natanek et al. (2013) showed wide heterogeneity in quadriceps type 69 
I fiber expression in 114 COPD patients evenly distributed across GOLD stages 2-4. These findings 70 
demonstrate that muscle oxidative capacity appears to be highly variable across disease severity, 71 
which underscores the need for simple methods to assess changes in muscle oxidative capacity in 72 
COPD patients independent from systemic effects of the disease. 73 
 74 
We aimed to address this using a non-invasive method based on near-infrared spectroscopy (NIRS; 75 
Motobe et al., 2004; Ryan et al., 2012). This technique provides measurement of the recovery rate 76 
constant (k) of muscle oxygen consumption (ǚ2), isolated from influences of circulatory or 77 
pulmonary function, and which is directly related to muscle oxidative capacity in single muscle 78 
fibers (r2=0.77; Wüst et al., 2013). Muscle k can be assessed by NIRS during ~6 minutes of recovery 79 
from brief contractions, using a series of intermittent arterial occlusions (5-10 s each); during 80 
occlusions, the rate of decline in the muscle tissue saturation index (TSI) is directly proportional to 81 
mǚ2. This technique has been validated in young healthy subjects against phosphocreatine 82 
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recovery kinetics and quadriceps muscle biopsy (Ryan et al., 2013, 2014). It has also been used to 83 
assess muscle oxidative capacity in spinal cord injury (Erickson et al., 2013), amyotrophic lateral 84 
sclerosis (Ryan et al., 2014) and chronic heart failure (Southern et al., 2015), among other 85 
conditions. However, to our knowledge, this technique has not been applied in COPD where muscle 86 
morphologic adaptations such as fat infiltration, fibrosis, inflammation, increased subcutaneous 87 
adipose, loss of type I fibers and mitochondrial density (Maltais et al., 2014) may hamper NIRS 88 
measurement of muscle oxidative capacity. 89 
 90 
The method relies on two competing assumptions: 1) that exercise is sufficiently intense to 91 
maximally activate mitochondrial oxidative enzymes and elicit a sufficient increase in ǚ2 92 
(Korzeniewski and Rossiter, 2015; Wüst et al., 2011, 2013); 2) that O2 delivery is not limiting to k 93 
(Haseler et al., 2004). This latter condition is especially important in COPD where poor systemic O2 94 
delivery, muscle capillary rarefaction and brief arterial occlusions may combine to reduce TSI below 95 
some critical threshold, thereby slowingǚ2 recovery kinetics. Test-retest reliability (intraclass 96 
correlation coefficient, ICC) of k in healthy subjects ranges from 0.26 to 0.68 (Ryan et al., 2012; 97 
Southern et al., 2014), and whether reliable measurements are possible in COPD is currently 98 
unknown. This is particularly important in relation to the expected effect magnitude of oxidative 99 
capacity loss in COPD (~10-50%; Meyer et al., 2013). Therefore, we aimed to determine the 100 
reliability of NIRS assessment of gastrocnemius muscle oxidative capacity in smokers with and 101 
without COPD. We hypothesized that test-retest variability in k would be sufficiently low to allow 102 
NIRS estimates of oxidative capacity to a useful method to detect COPD-related loss. Secondly, we 103 
aimed to identify correlates of high variability in repeated k measurement, if it occurred. These 104 
correlates may provide a basis for quality control of the NIRS muscle assessment. 105 
 106 
2. MATERIALS AND METHODS 107 
2.1 Participants 108 
Both smoking (Montes de Oca et al., 2008) and COPD (Maltais et al., 2014) have each been 109 
implicated in COPD-associated muscle dysfunction. Therefore, to account for the independent 110 
influence of smoking history, we sought current and former smokers with at least 10 pack-year 111 
smoking history to volunteer: 32 COPD patients (GOLD stage 1-4, defined by the criteria for the 112 
Global initiative for Chronic Obstructive Lung Disease) and 28 participants with normal spirometry 113 
(CON) (Table 1). This was an ancillary study of COPDGene (ClinicalsTrials.gov Identifier 114 
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NCT00608764), for which a complete list of inclusion and exclusion criteria is given in Regan et al. 115 
(2010). Participants were informed about the procedures and risks associated with the study, and 116 
gave written informed consent. The study was approved by the Institutional Review Board of Los 117 
Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, in accordance with the 118 
Declaration of Helsinki. 119 
 120 
2.2 Protocol 121 
Each participant visited the laboratory once, during which NIRS muscle oxidative capacity and a 122 
spirometry tests were performed.  123 
 124 
2.2.1 NIRS muscle oxidative capacity test. A wireless, portable, continuous-wave, spatially-resolved 125 
spectroscopy (SRS) NIRS device (PortaMon, Artinis, The Netherlands) was used to measure relative 126 
concentrations of deoxy-hemoglobin and deoxy-myoglobin (here termed HHb for simplicity) and 127 
oxy-hemoglobin and oxy-myoglobin (HbO2) in the tissues ~1.5 cm beneath the probe (interoptode 128 
distance was 3 cm). From these measurements relative changes in total hemoglobin and myoglobin 129 
(THb = HHb+HbO2) and the Hb difference (Hbdiff = HbO2-HHb) were calculated. In addition, the 130 
tissue saturation index (TSI, %) was measured using the SRS approach (using interoptode distances 131 
of 2-3 cm) (Ferrari et al., 2004).  132 
 133 
A modified NIRS protocol based on Ryan et al. (2012) was used. The participant lay supine and the 134 
NIRS probe was wrapped in plastic film, placed longitudinally on the belly of the right medial 135 
gastrocnemius, and secured with an elastic bandage. A 13 x 85 cm rapid-inflation pressure-cuff 136 
(SC12D, Hokanson, USA) was placed on the proximal thigh of the same leg and attached to an 137 
electronically-controlled rapid cuff-inflator (E20, Hokanson, USA). A pad was placed under the ankle 138 
such that the lower leg and NIRS probe was suspended above the bed. During the ~30 min 139 
assessment, the participant was asked to relax and refrain from moving the leg except when 140 
instructed.  141 
 142 
Initially, the participant was familiarized with the execution of cyclical plantar-flexion/relaxation 143 
exercise at ~1Hz, to activate the medial gastrocnemius against a manually applied resistance, and 144 
with the rapid-cuff inflation procedures. Repeated cuff inflations from low (~50 mmHg) to high 145 
(~250 mmHg) pressures were performed during this familiarization phase. Arterial occlusion was 146 
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determined from a tolerated cuff-pressure within the range of 230-300 mmHg (236±17 mmHg) that 147 
resulted in HHb rise, HbO2 fall and approximately constant THb over ~15-20 s.  148 
 149 
The measurement protocol began after 2-3 min of rest, where baseline TSI and SpO2 at a fingertip 150 
(Rad-5 Pulse Oximeter MasimoSET®, Masimo Co., Irvine, CA) were measured over 2 min. 151 
Subsequently, after having removed the pulse oximeter, the participant was instructed to execute 152 
10-12 cycles of plantar-flexion exercise, followed immediately by arterial occlusion until a steady-153 
state in TSI was reached (mean duration ~90 s; Figure 1). The cuff was then instantly deflated and 154 
muscle reoxygenation was recorded until a steady-state was reached (typically ~3 min). This 155 
procedure (the physiologic normalization, PN) identified the functional range of TSI under resting 156 
conditions from TSImin at the end of the sustained arterial occlusion to TSImax at the peak of the 157 
reactive hyperemia (Figure 1). Finally, the participant performed two oxidative capacity 158 
assessments. These consisted of: 1) cyclical plantar-flexion exercise to desaturate the muscle to a 159 
target of 50% of the PN amplitude (typically 10-15 s of contractions) (Hamaoka et al., 2007; McKully 160 
et al., 1994; Motobe et al., 2004; Ryan et al., 2012) (Figure 1); 2) a series of intermittent arterial 161 
occlusions (AO; 5 occlusions for 5 s, and 10 for 10 s, each separated by 5-20 s recovery). A single 162 
oxidative capacity assessment lasted ~6 minutes. The second repetition was conducted once a 163 
resting steady state was re-established (typically ~1 min). 164 
 165 
At the end of the procedure the skinfold at the NIRS site was measured to estimate adipose tissue 166 
thickness (ATT, mm) (Lange Skinfold Caliper, Beta Technology Inc., Santa Cruz, CA). 167 
 168 
2.2.2 Spirometry. Approximately 15 minutes before spirometric testing, participants inhaled two 169 
puffs of metered dose albuterol sulfate (ProAir HFA, Teva Respiratory, Horsham, PA, USA). 170 
Spirometry was performed in accordance with the American Thoracic Society guidelines (Miller et 171 
al., 2005) using a dual beam Doppler ultrasound-based spirometer (EasyOne Pro, Ndd Medical, 172 
Zürich, Switzerland) (Regan et al., 2010). FEV1 and forced vital capacity (FVC) were measured from 173 
the greatest FEV1 and FVC over up to eight maximum expiratory maneuvers, where the greatest two 174 
measurements were within 150 mL. 175 
 176 
2.3 Analyses 177 
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2.3.1 NIRS oxidative capacity test. During the repeated oxidative capacity tests, for each intermittent 178 
arterial occlusion the negative slope of TSI (%.s-1) was fitted by a linear function to estimate relative179 ǚ2 (Figure 2A,C). Note that during occlusion the rate of deoxygenation (the negative slope of TSI) 180 
is inversely proportional to ǚ2, and is therefore reported below as a positive value (%.s-1). The 181 ǚ2 exponential recovery rate constant (k, min-1) was estimated using non-linear least-squares 182 
regression (Figure 2B,D) (OriginPro v8.6, OriginLab Co., Northampton, USA) (Wüst et al., 2013). 183 
 184 
2.3.2 NIRS quality control. Low test-retest variability (>1 SD) was used as the quality control 185 
criterion. For those tests with reproducibility outside 1 SD, the potential for limitations in O2 186 
delivery and/or contraction-induced activation of mitochondrial oxidative phosphorylation during 187 
the oxidative capacity test were investigated to assess for physiologic contributors to test-retest 188 
variability. To determine a value of TSI during the sustained occlusion in the PN phase where the 189 
decline in TSI began to slow (a deflection in TSI; Figure 1B), a linear regression was applied from 190 
the onset of the sustained AO up to a point just before TSI deviated from linearity. This was 191 
investigated as a potential marker for the onset of O2 delivery limitation to ǚ2 during arterial 192 
occlusion. The lowest TSI (TSILOW) reached during each oxidative capacity test was recorded (both 193 
as an absolute muscle saturation and relative to the PN) and compared with the TSI deflection point 194 
(Figure 1). The increase in ǚ2 during contractions was estimated from the greatest ǚ2 195 
recorded during the oxidative capacity test, and expressed in absolute units (%.s-1) and as a fold-196 
change above the steady-state resting ǚ2 (measured at the end of the oxidative capacity test): a 197 
small increase or fold-change in ǚ2 may indicate insufficient contractile stimulus for 198 
mitochondrial oxidative phosphorylation and result in a low k. 199 
 200 
2.3.3 Statistics. A Sǯt test was used to identify differences between COPD and CON. A 201 
Bland-Altman analysis for repeated measurements was used to assess the agreement between the 202 
two ǚ2 recovery k assessments (Bland and Altman, 1999). Coefficient of variation (CV) and 203 
intraclass correlation coefficient (ICC) were used to assess within-subject test-retest reproducibility. 204 
Variables correlated with the difference between repeated-measures of k ('k) were sought by 205 
Spearman univariate linear regression analysis. Significant differences were accepted at P  ? 0.05. 206 
Results are presented as mean ± SD, unless otherwise specified. A Shapiro-ǯ(P  ? ?.05) and 207 
visual inspection of the histograms, Q-Q plots and box plots were performed to determine normal 208 
distribution of k values for both COPD and CON groups (COPD, P > 0.45; CON, P > 0.06). Statistical 209 
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analyses were performed using Prism v6.0f (GraphPad, San Diego, CA, USA) and SPSS v20 (IBM, 210 
Chicago, IL, USA). 211 
 212 
3. RESULTS 213 
3.1 Participant characteristics 214 
Four COPD patients were unable to successfully complete the NIRS muscle protocol: two could not 215 
tolerate the sustained arterial occlusion for the PN, and the ǚ2 k could not be confidently 216 
resolved in one repeat of two other COPD patients. These 4 COPD patients were excluded from 217 
further analysis. Results are reported from 28 COPD and 28 normal spirometry CON participants. 218 
Two COPD patients required nasal cannula O2 during the visit (at 3-4 L.min-1). Participant 219 
characteristics are shown in Table 1. CON were younger than COPD (60 ± 7 vs. 65 ± 8 years, P < 220 
0.05). 221 
 222 
3.2 Muscle near-infrared spectroscopy 223 
3.2.1 Resting muscle. Resting muscle TSI and ATT did not differ between COPD patients and CON 224 
(Table 1).  225 
 226 
3.2.2 Physiologic normalization (PN). In all COPD patients, PN ranged from a minimum of 22 % TSI to 227 
a maximum of 77 % TSI, with a mean range (max - min) of 32 ± 9 %. This was not different (P > 228 
0.05) than CON: PN ranged 19 to 81 %, with a mean of 32 ± 11 %.  229 
 230 
3.2.3 Muscle oxidative capacity (ǚ2 k). A total of 112 mǚ2 recovery kinetics assessments were 231 
performed for the study. On average, there was no difference between repeated k measurements 232 
within COPD or CON participants (Table 2). The individual test-retest reliability was not different 233 
between COPD (CV = 9.9%, ICC = 0.88) and CON (CV = 9.9%, ICC = 0.93) (Table 2, Figure 3). Power 234 
analyses (G*Power 3.1; Faul et al, 2007) revealed a 1-ș = 0.81 for comparison of k between groups 235 
(the primary outcome). In all participants, Bland-Altman limit of agreement analysis revealed low 236 
mean bias (-0.03min-1), and 95% confidence intervals of -0.58, 0.64 min-1 (Figure 4). We could 237 
detect no order effect between repeats of k measurement (P = 0.24; 1-tailed t-test). On average, 238 ǚ2 k was ~25% lower in COPD than CON (Table 2) and was diminished at all GOLD stages: CON, 239 
1.74 ± 0.71 min-1 (n=28); GOLD 1, 1.45 ± 0.36 min-1 (n=7); GOLD 2, 1.48 ± 0.37 min-1 (n=13); GOLD 3, 240 
1.22 ± 0.32 min-1 (n=5); and GOLD 4, 1.54 ± 0.41 min-1 (n=3).  241 
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 242 
3.2.4 NIRS test quality control. During the oxidative capacity test, the lowest TSI (TSILOW) in both 243 
repeats was typically achieved within the first or second AO (e.g., see Figure 1). In both COPD and 244 
CON, TSILOW averaged ~47% absolute (Table 3), equivalent to ~32% and ~29% of the PN range 245 
respectively. On average, the TSI deflection point occurred at 46 ± 9 % in COPD and 46 ± 11 % in 246 
CON. This meant that, typically (66% of tests), TSILOW was greater than TSI deflection point. In 38 247 
tests (27%) TSILOW was below TSI deflection point. 248 
 249 
In COPD, the peak ǚ2 during the oxidative capacity test was 1.38±0.59 %.s-1 and 1.51±0.88 %.s-1 250 
respectively for the first and second repetitions (equivalent to a 14±7 and 16±13 fold increase 251 
above the recovery steady-state, 0.12±0.12 %.s-1). Peak ǚ2 values during the oxidative capacity 252 
test in CON were 1.71±1.89 %.s-1 and 1.49±1.17 %.s-1 respectively for the first and second repeat, 253 
equivalent to a 18±12 and 16±11 fold increase above resting (0.10±0.05 %.s-1), and were not 254 
different compared with COPD (P = 0.68). 255 
 256 
Variables predictive of poor reproducibility were sought as potential quality control indices for the 257 
NIRS oxidative capacity test. Univariate linear regression analysis revealed that variability in 258 
repeated k measurements, assessed from the difference between the two k values ('k), was 259 
positively correlated with k (r2 = 0.17; P  ? 0.001): meaning faster ǚ2 kinetics were related to 260 
greater variably of measurement. However, other variables hypothesized to explain variability in k, 261 
including those expected to contribute to limitations in ǚ2 activation, O2 delivery, or NIRS signal 262 
sensitivity, such as minimum TSI during PN and TSILOW, age and resting TSI, PN maximum value and 263 ǚ2 fold change, did not show a strong association with 'k (P > 0.10). 264 
 265 
We investigated the characteristics of poorly-reproducible tests where 'k exceeded 1 SD (equal to 266 
the mean effect size for COPD; 'k > 0.3 min-1): thirteen participants (5 COPD, 8 CON) exceeded this 267 
variability threshold. These unreliable tests were characterized by a low ǚ2 (TSI = 1.15 ± 268 
0.44 %.s-1) and poor exercise deoxygenation (e.g. a high TSILOW value of 53.5 ± 5.8 %). Six of these 269 
participants had large adipose layer (ATT = 8.3 ± 3.0 mm) and six had high skin melanin, each likely 270 
limiting the volume of the muscle interrogated by the NIRS probe. In all these 13 participants, the 271 
lowest TSI during the test (TSILOW) was below the TSI deflection point, suggesting that low O2 272 
availability was not associated with muscle oxidative capacity assessment reliability. Excluding tests 273 
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on the basis of 'k > 0.3 min-1 improved k measurement reliability (CV = 7.0±4.3%, ICC = 0.98, n = 274 
43).  275 
 276 
4. DISCUSSION 277 
This is the first study to measure locomotor muscle oxidative capacity (from ǚ2 recovery rate 278 
constant, k) in a large group of smokers with or without COPD, using a non-invasive, relatively 279 
simple, short-duration assessment by NIRS. Fifty-six out of 60 participants (93%) tolerated the NIRS 280 
assessment and returned interpretable results. Overall these data showed: there was no mean bias 281 
between test-retest repeats of gastrocnemius k measurement by NIRS in both COPD patients and 282 
age-similar smokers without airflow obstruction; that individual test-retest reproducibility was 283 
high (CV = 9.9%, ICC = 0.9); and that k averaged 25 % less in COPD compared to smokers with 284 
normal spirometry. Despite known muscle morphologic adaptations including increased fat and 285 
fibrotic infiltration, inflammation, loss of type I fibers and mitochondrial density (Maltais et al., 286 
2014), our findings support that the NIRS assessment is a reliable method to detect COPD-related 287 
loss of muscle oxidative capacity.  288 
 289 
We also aimed to identify correlates of tests with reproducibility that lay outside 1 SD of the 290 
distribution of all tests, as potential features for quality control. 13 of 56 participants (5 COPD, 8 291 
CON) showed a high variability in k ('k > 0.3 min-1, which was the mean effect size of COPD). Poor 292 
reproducibly was not associated with presence of COPD. Poor reproducibility was explained 293 
principally by a small increase in ǚ2 and only modest deoxygenation during contractions. This 294 
suggests that insufficient contractile stimulus for mitochondrial activation and/or that the NIRS 295 
signal contained little light reflected from active muscle (large adipose layer in n=6, and high skin 296 
melanin content in n=6), may contribute to poor test quality. These findings indicate that a poor 297 
quality tests are related to an insufficient increase in ǚ2 during contractions, and not to the 298 
presence of an O2 delivery limitation, as might be anticipated in COPD. 299 
 300 
4.1 Muscle oxidative capacity in COPD 301 
We found that k in the gastrocnemius skeletal muscle was, on average, 25 % less (range ~12-30%) 302 
in COPD than smokers of a similar age but without pulmonary obstruction. This average is 303 
consistent with the ~10-50% lower muscle oxidative enzyme activity (e.g. citrate synthase) or 304 
oxidative capacity observed in quadriceps biopsy samples from COPD patients compared with 305 
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controls (Meyer et al., 2013), suggesting that the NIRS test provides a relevant non-invasive 306 
alternative to invasive biopsy assessments (Ryan et al., 2014). It is of note that k in our control 307 
group was 25% lower than non-smoking control participants in other studies using the same NIRS 308 
methods (non-smoker gastrocnemius k = ~2 min-1 equivalent to an oxidative capacity of ~250 309 
pmol.s-1.mg dry weight-1; Ryan et al., 2014). However, those studies almost exclusively included 310 
young participants aged 24-27 years, while our smokers ranged 49-77 years. Whether the 311 
apparently low muscle oxidative capacity in our study relates to the effects of long-term smoking, or 312 
alternatively to age or physical inactivity remains to be determined.  313 
 314 
While our study was not sufficiently powered to detect differences across disease severity, one 315 
outlier of the three GOLD 4 patients (k = 2.12 min-1) likely skewed a general trend for a progressive 316 
decline in oxidative capacity across GOLD severity classifications 2-4. Even so, the distribution of k 317 
values among the 28 COPD patients suggests that low k may occur at any GOLD stage, and therefore 318 
muscle dysfunction may not be solely associated with the disease severity in COPD (Maltais et al., 319 
2014; Wagner, 2006). The precise etiologies resulting in loss of muscle oxidative capacity in COPD 320 
awaits further research. Nevertheless, the 93% tolerability and good test-retest agreement of the 321 
NIRS test in COPD prove the feasibility and reliability of this approach for discriminating patients 322 
with poor muscle function i.e. gastrocnemius k value lower than the 2 min-1 reference for a healthy 323 
adult. Because the NIRS test is non-invasive, it may provide the opportunity for muscle assessment 324 
in large-cohort studies, which are needed to better identify the complex multifactorial etiology of 325 
muscle oxidative dysfunction in COPD. 326 
 327 
4.2 Variables influencing reproducibility of the NIRS muscle oxidative capacity test 328 
The NIRS assessment of muscle oxidative capacity relies on the observed linear proportionality 329 
between the recovery rate constant (k) of cellular ǚ2 and cellular oxidative capacity i.e. the ǚ2max 330 
of the muscle cells investigated (Wüst et al., 2013). The primary predictor in our study of poor k 331 
reproducibility was a high value for k (r2 = 0.17; P  ?0.001). This is likely a simple reflection of the 332 
limited ability to accurately model the recovery rate constant with a limited number of ǚ2 333 
measurements when ǚ2 kinetics are rapid. Nevertheless, this does not limit the ability of the test 334 
to detect abnormally low muscle oxidative capacity, which is the primary aim for studies of COPD 335 
patients or other conditions of chronic inactivity or disease. 336 
 337 
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The relationship between cellular recovery k and oxidative capacity in muscle is predictable based 338 
on first order rate reaction kinetics (Voet and Voet, 2004), as long as O2 concentration in muscle 339 
mitochondria remains non-limiting. However, recent studies suggest that control of oxidative 340 
phosphorylation in skeletal muscle in humans is not first order, and    Ǯ ǯ341 
activation of mitochondrial oxidative pathways is required to activate the enzymes limiting cellular 342 ǚ2max (Korzeniewski and Rossiter, 2015; Wüst et al., 2011). Thus, accurate measurement of 343 
oxidative capacity by NIRS relies on competing demands to achieve a sufficiently high level of 344 
muscle activity andǚ2 to release mitochondrial oxidative enzyme regulation, but to limit muscle 345 
activity to a sufficiently low level such that muscle mitochondrial O2 delivery does not become a 346 
limiting variable. Failure to meet either of these conditions would result in an erroneously low 347 
measurement of muscle oxidative capacity by NIRS. 348 
 349 
Using single muscle fibers from the frog suspended in a medium containing a high O2 concentration, 350 
Wüst et al. (2013) observed that, unlike poorly-oxidative fibers, ǚ2 recovery k of highly-oxidative 351 
fibers was dependent on the frequency of stimulation of the preceding contractions. A contractile 352 
protocol sufficient to elicit ~50% ǚ2max was required to release oxidative enzyme regulation to 353 
allow recovery k to become proportional to cellular oxidative capacity. The duration required of this 354 
contractile protocol was not assessed. The human medial gastrocnemius, the site of NIRS probes in 355 
our study, expresses a mixed fiber type distribution and contains both poorly and highly-oxidative 356 
muscle fibers. Therefore, a low mǚ2 response during muscle contractions would be predictive of a 357 
poor quality assessment and result in an erroneously low oxidative capacity. Consistent with this 358 
notion, in 13 of our participants the NIRS test results were poorly reproducible and in these there 359 
was a tendency (P = 0.20) for a low exercise-induced increase in ǚ2. This highlights the 360 
importance of ensuring high-intensity muscle contractions during the NIRS oxidative capacity 361 
assessment for validity of the test. 362 
 363 
As stated previously, another condition that must be satisfied for validity of the NIRS test is non-364 
limiting mitochondrial O2 delivery. Using 31P magnetic resonance spectroscopy to determine 365 
gastrocnemius PCr recovery kinetics from plantar flexion exercise (a proxy for ǚ2 k), Haseler et 366 
al. (2004) showed in young sedentary subjects that PCr recovery was not limited by O2 delivery 367 
under normoxic conditions. However, during hypoxic gas breathing, PCr recovery kinetics were 368 
slowed. It should be pointed out that the duration of exercise was 6 min, and therefore mǚ2 and 369 
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muscle deoxygenation were likely far greater than those observed in our study where exercise was 370 
limited to ~15 s. Nevertheless, were TSI to be driven below some limiting value, ǚ2 recovery k 371 
may become limited by O2 delivery in vivo, which would result in an erroneously low k. While the 372 
brief exercise in the NIRS test does not strain central cardiac or pulmonary limits for O2 delivery, 373 
age- or disease-related chronic adaptations, such as muscle capillary rarefaction, inflammation, 374 
anemia or reduced muscle myoglobin (Maltais et al., 2014), have the potential to limit muscle 375 
mitochondrial O2 concentration in COPD and therefore invalidate the NIRS assessment. However, 376 
we found that the lowest value of TSI measured during the NIRS assessment (TSILOW; typically 377 
reached during the 1st or 2nd post-exercise arterial occlusion) was not related to poor test-retest 378 
reliability of k. This suggests that outlying low k values are not consequent to O2 delivery limitation, 379 
at least down to TSILOW values of ~30% of the physiologic range. 380 
 381 
4.3 Quality control of the muscle NIRS oxidative capacity assessment 382 
In part, the beauty of the NIRS test of muscle oxidative capacity is that it relies on ǚ2 kinetics, and 383 
therefore does not require calibrated measurements. For this reason, one aim of this study was to 384 
identify variables that could be used as markers of quality control. We proposed to identify features 385 
within any tests that showed poor reproducibility. The strongest correlate of variability in repeated 386 
k measurements ('k) was the value of k itself, which does not provide a basis for quality control. To 387 
our surprise, however, we found no correlation between 'k and proposed quality assessments (e.g. 388 
increase in mǚ2 increase during contractions or low TSI during occlusions). This may reflect the 389 
overall strong test-retest reproducibility in COPD patients and controls. We therefore identified 13 390 
participants in whom variability exceeded 1 SD ('k > 0.3 min-1). Of these 13, there was a high 391 
prevalence of large ATT, high skin melanin content, low increase in mǚ2 and a small exercise-392 
induced deoxygenation. While these features alone do not form the basis of quality control, they 393 
highlight that patient physical characteristics limiting reflected light from active muscle tissue are 394 
likely partly responsible for reducing reproducibility of k measurements. Alternative NIRS systems, 395 
such as high-power time-resolved (TRS) NIRS, allow deeper penetration into muscle during rest and 396 
exercise (Okushima et al., 2015), and therefore may increase the reliability of mǚO2 recovery kinetic 397 
assessment in these patients.  398 
 399 
Based on our findings and experience, a few considerations emerge to inform quality control of the 400 
NIRS oxidative capacity test. First, the current best method of quality control is to perform the 401 
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measurement twice in the same visit. We propose that poorly-reproducible tests, where 'k > 0.3 402 
min-1, be repeated to reduce the influence of outlying results, and repeated measurements averaged. 403 
Careful attention should be made to the NIRS probe placement, to ensure that a muscle region is 404 
chosen that both minimizes the skinfold under the probe and maximizes the sampling of active 405 
muscle during contractions and recovery. Doppler ultrasound, skinfold calipers, muscle palpation 406 
during contraction and/or surface EMG may help to identify optimal NIRS probe placement. 407 
 408 
Exercise stimuli that result in a small increase ǚ2 and small reduction in saturation were 409 
associated with poor test reliability. Therefore, our data suggest that the risk to NIRS test validity of 410 
under-stimulating the muscle during dynamic contractions is greater than the risk of O2 limiting 411 
deoxygenation caused by contractions that are too intense or sustained. Thus, ensuring that the 412 
exercise-induced desaturation reaches a value of ~30-50% of the physiologic range (PN) helps in 413 
test quality assurance. This can be confirmed in real time by monitoring the TSI response to 414 
contractions and adjusting the intensity and/or duration of exercise (i.e. extending the duration 415 
beyond the ~10-15 s we used here) to achieve the desaturation target. This, of course, requires 416 
knowledge in the PN range prior to the oxidative capacity test, which is a modification to the 417 
protocol of Ryan et al. (2012) where the PN range measurement is performed last. This has the 418 
concern that a period of ischemia (even briefly) may affect mitochondrial function and therefore 419 
influence the assumptions inherent in the measurement of oxidative capacity fromǚ2 recovery 420 
kinetics e.g. an ischemic preconditioning effect (Crisafulli et al., 2011). Our findings, however, that 421 
muscle k in older controls (~1.75 min-1) and COPD (~1.45 min-1) were consistent with that 422 
predicted from biopsy studies (Meyer et al., 2013) suggest that brief ischemia does not harm the 423 
validity of the test.  424 
 425 
4.4 Clinical implications 426 
Low muscle oxidative capacity is associated with exercise intolerance in COPD and therefore may 427 
contribute to reduce physical activity and quality of life in these patients (Maltais et al., 2014; Meyer 428 
et al., 2013). We studied the gastrocnenius muscle as a primary locomotor muscle for walking, and 429 
which is also extensively activated during standing and in sway. Rehabilitation (cycling and 430 
walking) is known to ameliorate oxidative capacity deficits in quadriceps (Maltais et al., 1996) and 431 
is associated with a reduction of dyspnea and leg fatigue symptoms during exercise in COPD. 432 
Therefore, reliable measurements of skeletal muscle structure and function, independent of disease-433 
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related impairments in pulmonary function or muscle blood flow, are of crucial importance to 434 
monitor the peripheral consequences of COPD. This reliable, non-invasive, short-duration, relatively 435 
inexpensive and well-tolerated assessment of oxidative capacity in COPD muscle may also enable a 436 
better targeting to therapeutic strategies to improve physical activity, exercise tolerance and quality 437 
of life in these patients. 438 
 439 
4.5 Additional considerations 440 
Our approach focused on biological variability, in that test-retest precision of k was assessed in 441 
smokers with and without COPD with the same day and session, and the NIRS probe was not 442 
removed from the muscle between repeated tests. Southern et al. (2013) assessed the test-retest 443 
variability between consecutive days in young healthy participants, an approach that included the 444 
combined effects of both methodological and biological variability. This may partly explain why 445 
variability for k assessment in our study (ICC range 0.88-0.93; CV = 9.9 %) was higher than 446 
Southern et al. (2013) (ICC range 0.26-0.59; CV = 10.6 %). In addition, Southern et al. (2013) 447 
assessed reliability in 15 participants whereas our study investigated 56. This difference also 448 
contributes to the greater ICC found in our study. Nevertheless, our data show that the approach is 449 
reliable in COPD and older controls where muscle quality is reduced compared with young subjects.  450 
 451 
Furthermore, Southern et al. (2013) found greater day to day test-retest variability of the NIRS 452 
oxidative capacity test when using self-metered exercise (specifically, exercise against elastic 453 
resistance bands) compared with monitored exercise using a custom-built plantar flexion 454 
ergometer. We were specifically interested in assessing a pragmatic approach to the NIRS oxidative 455 
capacity test using self-metered exercise in order to assess the applicability of the assessment in the 456 
clinical setting without the requirement for additional specialized equipment. We used a manually-457 
applied resistance to plantar flexion administered by the same researcher in all participants. The 458 
intensity of the 10-15 contractions was assessed indirectly by feel and also monitored in the TSI 459 
trace in real time. This meant that the operator could instruct the participant to alter the intensity 460 
or duration of contractions Ǯoptimalǯ (and, 461 
by implication, ǚ2 response). We believe that this approach might have advantages over delivery 462 
of a standardized metered exercise dose in patients with chronic disease where there is wide 463 
variability in O2 delivery and O2 utilization responsiveness. Our high ICC values for k support the 464 
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suggestion, and that our pragmatic approach provides a reliable assessment of muscle oxidative 465 
capacity suitable for clinical research or routine assessment in COPD patients. 466 
 467 
4.6 Limitations 468 
There are few limitations to report for this study. The CON group were slightly, but significantly 469 
younger than the COPD patients (Table 1). It is possible that the younger age in CON may contribute 470 
to the mean effect size of k in COPD (-0.3 min-1). Nevertheless, the average difference in age was 471 
small (5 years on an average age of 65 years), and is not the only variable that affects muscle 472 
oxidative capacity. For example, physical activity, occupation, drug therapies and comorbidities are 473 
expected to play a significant role in the etiology of loss of muscle oxidative capacity in COPD 474 
(Maltais et al., 2014; Wagner, 2006). 475 
 476 
Two COPD patients used nasal cannula O2 delivery during the NIRS assessment. However, these 477 
participantsǯ data lay well within the range of the group as a whole ('k was -0.05 and -0.13 min-1). 478 
We could identify no reason additional to treat these data differently from the group. In addition, 479 
while baseline arterial O2 saturation was measured by pulse oximetry, we found no influence of 480 
SpO2 on the reproducibility of k. The brief single leg plantar-flexion contractions were insufficient to 481 
alter SpO2 and we found no differences in muscle HbO2 among the 13 participants with poor 482 
reproducibility of k and the rest of the group. We therefore believe that arterial oxygenation did not 483 
influence our results. However, this should be monitored in future studies to ensure that the 484 
assumption of constant SpO2 is met. 485 
 486 
Finally, we did not assess oxidative capacity from muscle biopsy in this study in relation to NIRS 487 
measures in these COPD patients. By their nature, NIRS assessment and muscle biopsy sample 488 
different muscle regions, complicating direct comparison. Assessment of quadriceps oxidative 489 
capacity by NIRS and biopsy was previously established in healthy young subjects (r > 0.6; Ryan et 490 
al., 2014). Validation of accuracy of the NIRS assessment of muscle oxidative capacity in COPD 491 
therefore awaits further investigation. 492 
 493 
5. CONCLUSION 494 
We found that a non-invasive NIRS-based assessment of oxidative capacity of gastrocnemius muscle 495 
was well tolerated and reliable in middle-aged to elderly smokers with or without COPD. Our data 496 
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were consistent with direct assessment of muscle citrate synthase activity or oxidative capacity 497 
from biopsy studies (Meyer et al., 2013) in that gastrocnemius k (a direct correlate of muscle 498 
oxidative capacity) was 25% lower in COPD than in smoker controls without pulmonary obstruction. 499 
We found high test-retest reliability of the NIRS oxidative capacity test in both COPD (CV = 9.9%; 500 
ICC = 0.88) and CON groups (CV = 9.9%; ICC = 0.93). Our attempts to identify objective markers of 501 
NIRS test quality were less successful: nevertheless, performance of repeated assessments in the 502 
same visit can identify outlying results, and these were associated with small ǚ2 and 503 
deoxygenation responses during dynamic contractions, and participants with a large skinfold or 504 
high skin melanin. Together these data suggest that poor-quality assessments occur when the 505 
exercise stimulus is insufficient for mitochondrial activation and/or the NIRS signal contains little 506 
light reflected from active muscle. Low post-contraction TSI was unrelated to NIRS test reliability, 507 
suggesting that O2 supply is sufficient for NIRS test validity at least down to TSI of ~30% of the 508 
individuals physiologic range. Therefore it is recommended to err towards a more intense exercise 509 
rather than the maintenance of a high muscle oxygenation to optimize NIRS assessment of muscle 510 
oxidative capacity. Our findings support the reliability of non-invasive muscle oxidative capacity 511 
assessment by NIRS in COPD, which may be helpful to track the efficacy of interventions in COPD 512 
such as pulmonary rehabilitation that are designed to redress skeletal muscle dysfunction. 513 
514 
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FIGURE CAPTIONS 648 
 649 
Figure 1: Tissue saturation index (TSI, %) changes during the NIRS muscle assessment. Panel 650 
A. Protocol phases, and the parameter calculated from the analyses of TSI signal changes, are 651 
indicated at the bottom of the graph. Grey shading indicates brief dynamic plantar-flexion exercise. 652 
AO = arterial occlusion; max and min = highest and lowest TSI values during the Physiologic 653 
Normalization (PN) phase; TSILOW = lowest saturation value reached during oxidative capacity 654 
assessments (for further details see Methods). Panel B. Expansion of panel A to illustrate the linear 655 
regression to determine the deflection point of muscle TSI (arrow) during the sustained arterial 656 
occlusion (AO). Grey shading indicates brief dynamic plantar-flexion exercise.  657 
 658 
Figure 2: ȋǡȌ ȋǡȌǯ  659 
muscle oxidative capacity assessment. Panels A and C show the TSI profiles during dynamic 660 
exercise, and intermittent arterial occlusion during recovery. Panels B and D show the calculated 661 
muscle ǚ2 recovery profiles and kinetic fit (dashed line). The letters (a-e) are given to illustrate 662    ǚ2 value is derived from respective TSI negative slopes during 663 
intermittent occlusions. The grey area (EX) indicates the brief dynamic exercise.W(sec) is the ǚ2 664 
time constant determined by non-linear least-squares regression. k, is the rate constant, which is 665 
linearly related to muscle oxidative capacity (k = (1/W min-1). 666 
 667 
Figure 3: Muscle oxidative capacity (k) test-retest analyses. Comparison of muscle k inferred from 668 
the two repetitions of muscle ǚ2 recovery kinetics in COPD (n = 28) and controls, CON (n = 28). 669 
Continuous line is the linear regression. Dotted line is the line of identity (x = y). 670 
 671 
Figure 4: Bland-Altman plot of the agreement between repeated measurements of muscle ǚ2 672 
recovery rate constant (k). Closed symbols are COPD patients (n = 28) and open symbols are controls 673 
(CON, n = 28). Horizontal dashed lines indicate the 95% limits of agreement (range -0.58, 0.64 min-1). 674 
 675 
 676 
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TABLES 678 
 679 
Table 1: Participant characteristics 680 
COPD CON
N. 28 28
Age (yrs) 65 (±8)   60 (±7) *
Weight (kg) 76 (±15) 79 (±17)
Height (cm) 171 (±11) 170 (±8)
BMI (kg/m2) 26 (±5) 27 (±5)
Gender (M/F) 17/11 16/12
Race (AA/NHW) 5/23 15/13
FVC (L) 3.3 (±0.9) 3.5 (±0.8)
FEV1 (L) 1.8 (±0.7) 2.8 (±0.6)
FEV1 %pred 63.9 (±23.4) 97.9 (±13.6) *
SpO2 (%) 97 (±1.6) 98 (±1.1)
GOLD stage N. (1/2/3/4) 7/13/5/3
Saturation (TSI) (%) 66 (±6) 68 (±5)
ATT (mm) 2.3 (±1.9) ¶ 2.8 (±1.9) ם
Data are mean (±SD). CON = controls; BMI = body mass index; M = male; F = female;
TSI = tissue saturation index; ATT = adipose tissue thickness
*
 
Svs.  COPD patients; ¶ = COPD n=21; ם = CON n=18
Resting Muscle Characteristics
Characteristics
FEV1 = forced expiratory volume in 1st second; SpO2 = arterial oxygen saturation; 
AA = African American; NHW = Non Hispanic White; FVC = forced vital capacity; 
 681 
 682 
683 
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Table 2: Reproducibility and coefficient of variation (CV) of gastrocnemius muscle oxidative 684 
capacity assessed by near-infrared spectroscopy, in smokers with and without COPD. 685 
 686 
% P
COPD 1.45 (±0.38) 1.42 (±0.36) 9.85 0.88 N.S.
CON 1.75 (±0.70) * 1.72 (±0.70) * 9.94 0.93 N.S.
 CV = coefficient of variation; ICC = intraclass correlation coefficient.
SYV&23'SDWLHQWV
k (min-1) 1st vs . 
2nd rep
CV ICC
1st rep 2nd rep
Data are mean (±SD). CON = controls; k  = proportional to muscle oxidative capacity;
 687 
 688 
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 26 
Table 3: Near-infrared spectroscopy tissue saturation index (TSI) variables of the gastrocnemius 690 
during post-contraction intermittent arterial occlusion. Mean and range of the saturation nadir 691 
(TSILOW, %) and relative peak muscle oxygen consumption (mǚO2, %.s-1) during repeated tests in 692 
smokers with and without COPD. 693 
 694 
TSILOW P9ࡆ O2 TSILOW P9ࡆ O2 TSILOW P9ࡆ O2
% % s-1 % % s-1 % %
COPD 47.5 1.38 46.7 1.51 3.92 16.11
í í í í
CON 47.4 1.71 42.2 1.49 5.25 17.65
í í í í
Data are mean (range). CON = controls; TSILOW = lowest value reached by tissue saturation index during
the arterial occlusions series; mV'O2 = muscle oxygen consumption
1st repetition 2nd repetition CV  
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